HK1154652A1 - Methods of prognosis in chronic kidney disease - Google Patents

Methods of prognosis in chronic kidney disease

Info

Publication number
HK1154652A1
HK1154652A1 HK11108644.0A HK11108644A HK1154652A1 HK 1154652 A1 HK1154652 A1 HK 1154652A1 HK 11108644 A HK11108644 A HK 11108644A HK 1154652 A1 HK1154652 A1 HK 1154652A1
Authority
HK
Hong Kong
Prior art keywords
prognosis
methods
kidney disease
chronic kidney
chronic
Prior art date
Application number
HK11108644.0A
Other languages
English (en)
Inventor
Samuel Norbert Breit
David Alexander Brown
Original Assignee
St Vincents Hosp Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008905617A external-priority patent/AU2008905617A0/en
Application filed by St Vincents Hosp Sydney filed Critical St Vincents Hosp Sydney
Publication of HK1154652A1 publication Critical patent/HK1154652A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3624—Level detectors; Level control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK11108644.0A 2008-10-31 2011-08-16 Methods of prognosis in chronic kidney disease HK1154652A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2008905617A AU2008905617A0 (en) 2008-10-31 Methods of prognosis in chronic kidney disease
PCT/AU2009/001413 WO2010048670A1 (en) 2008-10-31 2009-10-29 Method of prognosis in chronic kidney disease

Publications (1)

Publication Number Publication Date
HK1154652A1 true HK1154652A1 (en) 2012-04-27

Family

ID=42128127

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11108644.0A HK1154652A1 (en) 2008-10-31 2011-08-16 Methods of prognosis in chronic kidney disease

Country Status (8)

Country Link
US (3) US20120107420A1 (de)
EP (1) EP2350669B9 (de)
JP (1) JP5444363B2 (de)
CN (1) CN102203619B (de)
CA (1) CA2740632A1 (de)
ES (1) ES2434996T3 (de)
HK (1) HK1154652A1 (de)
WO (1) WO2010048670A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2388594A1 (de) * 2010-05-17 2011-11-23 Roche Diagnostics GmbH Mittel auf GDF-15-Basis sowie Verfahren zur Überlebens- und Genesungsvorhersage bei akuter Entzündung
AU2012240102C1 (en) 2011-04-08 2016-09-08 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
EP2783213B1 (de) * 2011-11-22 2017-09-13 Astute Medical, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
CN104204218A (zh) 2012-01-26 2014-12-10 安姆根有限公司 生长分化因子15 (gdf-15)多肽
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
KR101355281B1 (ko) 2012-06-27 2014-01-27 문용수 유출 혈액의 수분량 변화에 의한 사후경과시간 예측 방법
CN103890807B (zh) * 2012-10-16 2016-12-21 东芝医疗系统株式会社 死因推测装置及其死因推测方法
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
KR101993714B1 (ko) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
ES2521841B1 (es) * 2013-05-08 2015-09-09 Instituto De Investigación Sanitaria - Fundación Jiménez Díaz Procedimiento de diagnóstico y pronóstico de la enfermedad renal crónica en un sujeto humano
BR112016002213A2 (pt) 2013-07-31 2017-08-29 Amgen Inc Construtos do fator 15 de diferenciação de crescimento (gdf-15)
EP3044587B1 (de) * 2013-09-09 2019-02-27 Chu Sainte-Justine Verfahren zur behandlung und prognose von untergruppen von skoliosepatienten
US10274502B2 (en) 2013-11-04 2019-04-30 The Regents Of The University Of Michigan Biomarkers and methods for progression prediction for chronic kidney disease
CA2944990A1 (en) 2014-04-09 2015-10-15 The Regents Of The University Of California Protein biomarkers for immune assessment and prediction of transplant rejection
US20170137506A1 (en) * 2014-06-20 2017-05-18 Aveo Pharmaceuticals, Inc. Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
AP2016009663A0 (en) 2014-07-30 2016-12-31 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
EP3922259A1 (de) * 2014-10-30 2021-12-15 Acceleron Pharma Inc. Verfahren und zusammensetzungen mit gdf15-polypeptiden zur erhöhung der roten blutkörperchen
TN2017000113A1 (en) 2014-10-31 2018-07-04 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
EP3285811A1 (de) * 2015-04-21 2018-02-28 Institut Gustave Roussy Therapeutische verfahren, produkte und zusammensetzungen zur hemmung von znf555
EP3316159A4 (de) 2015-06-25 2019-08-14 Advanced Telecommunications Research Institute International Vorhersagevorrichtung auf basis eines mit mehreren organen assoziierten systems und vorhersageprogramm
US11229771B2 (en) 2015-07-20 2022-01-25 Roivios Limited Percutaneous ureteral catheter
US10765834B2 (en) 2015-07-20 2020-09-08 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
RU2720403C2 (ru) 2015-07-20 2020-04-29 Стратака Системз Лимитед, Мт Мочеточниковый катетер и мочепузырный катетер и способы создания отрицательного давления для увеличения почечной перфузии
US10493232B2 (en) 2015-07-20 2019-12-03 Strataca Systems Limited Ureteral catheters, bladder catheters, systems, kits and methods for inducing negative pressure to increase renal function
US10512713B2 (en) 2015-07-20 2019-12-24 Strataca Systems Limited Method of removing excess fluid from a patient with hemodilution
US11541205B2 (en) 2015-07-20 2023-01-03 Roivios Limited Coated urinary catheter or ureteral stent and method
US11040180B2 (en) 2015-07-20 2021-06-22 Strataca Systems Limited Systems, kits and methods for inducing negative pressure to increase renal function
GB201512733D0 (en) * 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
US11040172B2 (en) 2015-07-20 2021-06-22 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US12064567B2 (en) 2015-07-20 2024-08-20 Roivios Limited Percutaneous urinary catheter
US10918827B2 (en) 2015-07-20 2021-02-16 Strataca Systems Limited Catheter device and method for inducing negative pressure in a patient's bladder
US10926062B2 (en) 2015-07-20 2021-02-23 Strataca Systems Limited Ureteral and bladder catheters and methods of inducing negative pressure to increase renal perfusion
US10531837B1 (en) 2015-09-25 2020-01-14 Cerner Innovation, Inc. Predicting chronic kidney disease progression
US12057228B1 (en) * 2015-12-30 2024-08-06 Cerner Innovation, Inc. Predicting newly incident chronic kidney disease
EP3466446B1 (de) * 2016-03-29 2023-12-27 Karydo Therapeutix, Inc. Pharmazeutische zusammensetzung oder nahrungsmittelzusammensetzung und verfahren zur beurteilung der wirkung eines wirkstoffs in vivo
CN109196119A (zh) 2016-03-29 2019-01-11 株式会社国际电气通信基础技术研究所 用以预防或治疗选自由肾功能减退、慢性肾病和肾衰竭组成的组中的至少一种疾病的活性组分的候选物质的筛选方法
SG11201807279QA (en) 2016-03-31 2018-09-27 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
US11312766B2 (en) * 2016-04-27 2022-04-26 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
US20180059115A1 (en) * 2016-08-05 2018-03-01 The Wistar Institute Of Anatomy And Biology Methods for monitoring polymorphonuclear myeloid derived suppressor cells, and compositions and methods of treatment of cancer
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
JP2020531159A (ja) 2017-08-25 2020-11-05 ストラタカ システムズ リミテッド 尿路からの尿の除去を促進するための留置ポンプ
AU2019253462A1 (en) 2018-04-09 2020-11-26 Amgen Inc. Growth differentiation factor 15 fusion proteins
CN108363907B (zh) * 2018-05-09 2022-01-18 中国科学院昆明动物研究所 一种基于多基因表达特征谱的肺腺癌个性化预后评估方法
CN113270192A (zh) * 2021-04-19 2021-08-17 浙江大学 基于动静态数据结合与深度自编码器的血透风险预测系统
JPWO2022264804A1 (de) * 2021-06-16 2022-12-22

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003599A1 (en) 1992-08-04 1994-02-17 Sagami Chemical Research Center HUMAN cDNA AND PROTEIN WHICH SAID cDNA CODES FOR
US6180602B1 (en) 1992-08-04 2001-01-30 Sagami Chemical Research Center Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent
WO1995014772A1 (fr) 1993-11-12 1995-06-01 Kenichi Matsubara Signature genique
JPH07250688A (ja) 1994-01-28 1995-10-03 Sagami Chem Res Center ＴＧＦ−βスーパーファミリー蛋白質をコードするヒト新規ｃＤＮＡ
JPH07258293A (ja) 1994-03-23 1995-10-09 Asahi Chem Ind Co Ltd 新規な蛋白質ならびにその製造方法
US5994102A (en) 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
WO1996018730A1 (en) 1994-12-15 1996-06-20 Human Genome Sciences, Inc. Prostatic growth factor
US6521227B1 (en) 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
DE69637844D1 (de) 1995-06-22 2009-04-09 St Vincent S Hospital Sidney L Neues tgf-beta-ahnliches cytokin
US6524802B1 (en) 1996-03-29 2003-02-25 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-14
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
AU1276899A (en) 1997-10-23 1999-05-10 Fibrogen, Inc. Type ix collagen antibody and related uses
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
PT1179067E (pt) 1999-05-17 2007-01-31 Biopharm G Biotechnolo Entwi V Propriedades neuroprotectoras de gdf-15, um membro da superfamília de tgf-beta
ATE470863T1 (de) 2000-04-20 2010-06-15 St Vincents Hosp Sydney Diagnostischer assay mit makrophagenhemmendem zytokin-1 (mic-1)
WO2002059373A2 (en) 2001-01-23 2002-08-01 Irm, Llc Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
WO2002092124A1 (en) 2001-05-11 2002-11-21 Wyeth Methods for diagnosing and treating ischemia and reperfusion injury and compositions thereof
AU2003228811A1 (en) 2002-05-01 2003-11-17 Irm Llc Methods for discovering tumor biomarkers and diagnosing tumors
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US7157235B2 (en) 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
ES2518865T3 (es) * 2004-04-13 2014-11-05 St Vincent's Hospital Sydney Limited Agente de inhibición de MIC-1
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
WO2007112330A2 (en) 2006-03-24 2007-10-04 Diadexus, Inc. Compositions and methods for detection, prognosis and treatment of colon cancer
AU2008286706B2 (en) * 2007-08-16 2014-03-06 Garvan Institute Of Medical Research Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity
EP2209486A1 (de) * 2007-10-09 2010-07-28 St Vincent's Hospital Sydney Limited Verfahren zur behandlung von kachexie mit entfernung oder inaktivierung von makrophagen hemmendem zytokin-1
JP5272011B2 (ja) * 2007-10-22 2013-08-28 セントビンセンツ ホスピタル シドニー リミテッド 予後判定の方法
AU2008316317B2 (en) 2007-10-23 2015-04-30 Clinical Genomics Pty. Ltd. A method of diagnosing neoplasms
WO2009141357A1 (en) * 2008-05-20 2009-11-26 Roche Diagnostics Gmbh Gdf-15 as biomarker in type 1 diabetes
WO2011050407A1 (en) 2009-10-28 2011-05-05 St Vincent's Hospital Sydney Limited Methods of diagnosing and prognosing colonic polyps

Also Published As

Publication number Publication date
WO2010048670A1 (en) 2010-05-06
US20170023587A1 (en) 2017-01-26
US10705096B2 (en) 2020-07-07
EP2350669A4 (de) 2012-05-09
US20120107420A1 (en) 2012-05-03
CN102203619B (zh) 2015-12-16
EP2350669B1 (de) 2013-08-14
ES2434996T3 (es) 2013-12-18
ES2434996T9 (es) 2014-09-08
JP2012507012A (ja) 2012-03-22
EP2350669B9 (de) 2014-06-11
JP5444363B2 (ja) 2014-03-19
CN102203619A (zh) 2011-09-28
CA2740632A1 (en) 2010-05-06
EP2350669A1 (de) 2011-08-03
US20140205684A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
HK1154652A1 (en) Methods of prognosis in chronic kidney disease
HK1243462A1 (zh) 在體液中檢測疾病或病症標誌的方法
HK1202155A1 (en) Prognostic biomarkers for the progression of primary chronic kidney disease
IL216804A0 (en) Methods for treating chronic kidney disease
IL193099A0 (en) Method of treating chronic kidney disease
IL233023A (en) Methods for characterizing cancer in a patient
EP2358731A4 (de) Verfahren bezogen zu modifiziertem glycans
GB2459367B (en) Valves for use in wells
PT2209893E (pt) Uso de aptâmeros em proteómica
HK1142128A1 (en) Methods of prognosis
EP2257592A4 (de) Reduktion von aldehyden in aminen
EP2179306A4 (de) Bestimmung von formationseigenschaften
GB0805560D0 (en) Media level determination
IL201054A0 (en) New methods
EP2318508A4 (de) Bestimmung der integrität einer rna
ZA201000271B (en) Gaming system having graphical feature interface
IL211882A0 (en) Methods for determining sodium-proton-exchanger ligand efficiency
ZA201007982B (en) Gear pumps and methods for using gear pumps
EP2342355A4 (de) Verfahren zur verwendung von biomarkern
EP2312322A4 (de) Mikrochip
FI20070545A0 (fi) Lietelannan fosforipitoisuuden alentaminen
AU2008905617A0 (en) Methods of prognosis in chronic kidney disease
GB0913977D0 (en) Methods of improving pump performance
GB0711140D0 (en) New methods
AU3807P (en) Ivoryduchess Prunus persica